In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S.

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Shares of Sun Pharma rose 2 percent to Rs 1,711 in morning trade on July 15, extending their gains for a third straight ...

GAIL signs long-term LNG agreement, Sun Pharma settles litigation, LIC appoints new CEO, Tata Group's green steel project ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...